Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study.

Joana Vidal Maria Concepción Fernández-Rodríguez David Casadevall Pilar García Alfonso David Páez Marta Guix Vicente Alonso María Teresa Cano Cristina Santos Gema Durán Elena Elez Fernandez Jose Luis Manzano Rocio Garcia-Carbonero María Reyes Ferreiro Ferran Losa Estela Pineda Losada Javier Sastre Fernando Rivera Beatriz Bellosillo Josep Tabernero Enrique Aranda Ramón Salazar Clara Montagut

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

ctDNA detects early molecular response and predicts benefit to chemotherapy plus cetuximab. A comprehensive NGS-based approach is recommended to integrate information on total disease burden and resistant mutations.

Keyphrases

metastatic colorectal cancer
locally advanced
rectal cancer
squamous cell carcinoma
high throughput
radiation therapy
healthcare
ionic liquid
risk factors
chemotherapy induced
circulating tumor